Cutaneous T-cell lymphoma: Biologic targets for therapy

Jaehyuk Choi, Francine Foss*

*Corresponding author for this work

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrate stigmata of T-cell activation. As the disease progresses, there appears to be an accumulation of genetic and epigenetic changes that may contribute to the aggressiveness of the disease. Furthermore, the persistence of tumor appears to require escape from cancer immunosurveillance. This process likely requires modulation of the host immune system and skewing of the immune cells away from a cytotoxic phenotype. Each of these steps in disease pathogenesis offers a potential object for targeted therapies. This article reviews the recent research into the design and use of targeted therapies for CTCL.

Original languageEnglish (US)
Pages (from-to)272-277
Number of pages6
JournalCurrent Hematologic Malignancy Reports
Volume2
Issue number4
DOIs
StatePublished - Dec 1 2007

Fingerprint

Cutaneous T-Cell Lymphoma
Biological Therapy
Immunologic Monitoring
Christianity
Neoplasms
Skin
Langerhans Cells
T-Cell Antigen Receptor
Epigenomics
Immune System
Research Design
Up-Regulation
Lymphocytes
Cytokines
T-Lymphocytes
Phenotype
Therapeutics
Population

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{fb4f946e69e040abb95376a55e57e017,
title = "Cutaneous T-cell lymphoma: Biologic targets for therapy",
abstract = "Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrate stigmata of T-cell activation. As the disease progresses, there appears to be an accumulation of genetic and epigenetic changes that may contribute to the aggressiveness of the disease. Furthermore, the persistence of tumor appears to require escape from cancer immunosurveillance. This process likely requires modulation of the host immune system and skewing of the immune cells away from a cytotoxic phenotype. Each of these steps in disease pathogenesis offers a potential object for targeted therapies. This article reviews the recent research into the design and use of targeted therapies for CTCL.",
author = "Jaehyuk Choi and Francine Foss",
year = "2007",
month = "12",
day = "1",
doi = "10.1007/s11899-007-0037-8",
language = "English (US)",
volume = "2",
pages = "272--277",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "4",

}

Cutaneous T-cell lymphoma : Biologic targets for therapy. / Choi, Jaehyuk; Foss, Francine.

In: Current Hematologic Malignancy Reports, Vol. 2, No. 4, 01.12.2007, p. 272-277.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cutaneous T-cell lymphoma

T2 - Biologic targets for therapy

AU - Choi, Jaehyuk

AU - Foss, Francine

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrate stigmata of T-cell activation. As the disease progresses, there appears to be an accumulation of genetic and epigenetic changes that may contribute to the aggressiveness of the disease. Furthermore, the persistence of tumor appears to require escape from cancer immunosurveillance. This process likely requires modulation of the host immune system and skewing of the immune cells away from a cytotoxic phenotype. Each of these steps in disease pathogenesis offers a potential object for targeted therapies. This article reviews the recent research into the design and use of targeted therapies for CTCL.

AB - Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrate stigmata of T-cell activation. As the disease progresses, there appears to be an accumulation of genetic and epigenetic changes that may contribute to the aggressiveness of the disease. Furthermore, the persistence of tumor appears to require escape from cancer immunosurveillance. This process likely requires modulation of the host immune system and skewing of the immune cells away from a cytotoxic phenotype. Each of these steps in disease pathogenesis offers a potential object for targeted therapies. This article reviews the recent research into the design and use of targeted therapies for CTCL.

UR - http://www.scopus.com/inward/record.url?scp=38349068645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349068645&partnerID=8YFLogxK

U2 - 10.1007/s11899-007-0037-8

DO - 10.1007/s11899-007-0037-8

M3 - Review article

C2 - 20425380

AN - SCOPUS:38349068645

VL - 2

SP - 272

EP - 277

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 4

ER -